Since 2007, the European Centre for Disease Prevention and Control (ECDC) has supported I-MOVE (influenza monitoring vaccine effectiveness), a network to monitor seasonal and pandemic influenza vaccine effectiveness (IVE) in the European Union (EU) and European Economic Area (EEA). To set up I-MOVE, we conducted a literature review and a survey on methods used in the EU/EEA to measure IVE and held expert consultations to guide the development of generic protocols to estimate IVE in the EU/EEA. On the basis of these protocols, from the 2008/09 season, I-MOVE teams have conducted multicentre case-control, cohort and screening method studies, undertaken within existing sentinel influenza surveillance systems. The estimates obtained include effectiveness against medically attended laboratory-confirmed influenza and are adjusted for the main confounding factors described in the literature. I-MOVE studies are methodologically sound and feasible: the availability of various study designs, settings and outcomes provides complementary evidence, facilitating the interpretation of the results. The IVE estimates have been useful in helping to guide influenza vaccine policy at national and European level. I-MOVE is a unique platform for exchanging views on methods to estimate IVE. The scientific knowledge and experience in practical, managerial and logistic issues can be adapted to monitor surveillance of the effectiveness of other vaccines.
Human influenza viruses are subject to frequent antigenic changes. For this reason, the influenza vaccine is the only vaccine reformulated each year to optimise antigenic match between the vaccine and circulating virus strains. The seasonal influenza vaccine is a trivalent vaccine, which currently includes strains of the A subtypes H3N2 and H1N1 and one strain of B virus [1] . The World Health Organization (WHO) issues recommendations in February for which strains should be included in the seasonal vaccine for the northern hemisphere. Once these recommendations have been made, vaccine producers need at least six months to manufacture and distribute the seasonal vaccine. In a pandemic situation, pandemic strain-specific vaccines become available four to six months after the beginning of the vaccine development. During the 2009 pandemic, the influenza A(H1N1)pdm09 strain was identified in April 2009 but the first pandemic vaccines started to become available in Europe only at the end of September 2009. Consequently, antigenic changes in circulating viruses may occur before the start of the vaccination campaigns and can result in a poor match between vaccine (seasonal and pandemic) and circulating strains.
In Europe, seasonal influenza viruses circulate in the cold months, generally between October and April. National influenza surveillance networks have been established since the 1950s based on sentinel practitioner networks. In 1995, the European Influenza Surveillance Scheme was established [2] . Since 2008, the European Centre for Disease Prevention and Control (ECDC) has coordinated the European Influenza Surveillance Network (EISN) [3] . Sentinel practitioners include general practitioners (GPs), paediatricians or other physicians, depending on the European Union (EU) Member State.
Influenza vaccination is the most effective preventive measure available against influenza infection. In May 2003, the World Health Assembly recommended vaccination for all people at high risk, defined as the elderly and persons with underlying diseases. WHO Member States committed to attain a vaccination coverage in the elderly population of at least 50% by 2006 and 75% by 2010 [4] . In December 2009, the Council of the EU issued a recommendation encouraging EU Member States to take action to reach the target of 75% vaccine coverage of the older age groups recommended by WHO and if possible of other risk groups, preferably by 2014-2015 [5] .
Influenza vaccination campaigns are conducted every year in the EU Member States, targeting a high number of individuals [6] . As with any public health intervention, it is important to evaluate their effectiveness. The existence of robust systems to monitor the safety and effectiveness of vaccines is a major determinant of the success of vaccination programmes. Because of antigenic drift, vaccine effectiveness cannot be inferred from estimates from previous seasons. In order to evaluate influenza vaccine effectiveness (IVE) in Europe, ECDC developed a network to monitor seasonal and pandemic IVE in the EU and European Economic Area (EEA). In this article, we describe the phases undertaken to establish the network, its organisation and the main lessons learnt in the first four influenza seasons.
I-MOVE preparatory phase
In 2007, under the ECDC umbrella, the network -composed initially of 18 European public health institutes and EpiConcept, the coordinating hub -was set up. Named I-MOVE (influenza monitoring vaccine effectiveness) in Europe, it aimed to measure IVE on a routine basis. The study methods had to be simple, sustainable in a context of limited budget, adapted to the EU/ EEA context and scientifically robust.
The objectives of the first preparatory phase of I-MOVE were to identify the most appropriate observational study designs to measure IVE routinely in the EU/EEA and to identify key methodological issues to be considered in the study protocols. To achieve these objectives, EpiConcept conducted the following: (i) a survey among EU/EEA Member States to identify IVE studies performed in Europe and potential data sources for future studies; (ii) a literature review on methods used to estimate IVE; and (iii) three expert consultations. The methods and results of this phase have been described elsewhere [7] . In brief, the main conclusions were that EU/EEA influenza sentinel surveillance systems seemed to provide a sustainable platform suitable for case-control studies and screening method studies monitoring IVE. In Member States or regions with computerised primary care databases, cohort studies could be conducted to measure IVE against different outcomes.
To control for positive and negative confounding, a minimum set of variables had to be collected in all studies [8] . In addition, as using a specific outcome reduces bias, it was recommended to measure IVE against laboratory-confirmed influenza.. To minimise selection bias, sentinel practitioners were to select systematically the patients to swab.
On the basis of these conclusions, EpiConcept and ECDC developed and published generic case-control, cohort, screening method and cluster investigation protocols for IVE studies [9] [10] [11] 
I-MOVE organisational aspects
In the first four seasons, 26 partner institutions from 17 EU/EEA Member States participated in I-MOVE (Figure 1) . Each institution designated an I-MOVE focal point, most of them being influenza experts coordinating the national influenza surveillance system. A total of 13 study site teams have conducted IVE studies: some use several study designs in the same site during the same season ( Table 1 ). The functioning of the I-MOVE network has to date been funded by ECDC and the IVE studies co-funded by ECDC and the study sites. EpiConcept coordinates the I-MOVE activities. The network collaborates with teams conducting IVE studies in Canada, USA and Australia.
Technical workshops are organised during the influenza season among I-MOVE study sites to discuss the preliminary results, to plan the final analysis and to define the publication strategy. Periodically, follow-up videoconferences are organised between study sites. The whole network meets annually at the end of the influenza season to share the IVE estimates and discuss practical and methodological issues related to the studies. Since the 2009/10 season, the last day of the meeting has been open to decision-makers (European Medicines Agency (EMA), European Commission, WHO) and vaccine manufacturers. An I-MOVE website is in place with three different levels of access: unrestricted, restricted to I-MOVE partner institutions, restricted to I-MOVE study sites [12] .
Each study site defines its strategy to communicate its results. EpiConcept, in close collaboration with ECDC, coordinates the publication of the multicentre casecontrol pooled results. Since 2008, I-MOVE IVE results have been published in peer-reviewed journals [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] .
I-MOVE implementation phase (2008/9 to 2011/12)
The study designs used within I-MOVE are case-control studies, cohort studies using primary care databases and screening method studies.
Case-control studies, including multicentre case-control study Nine EU sites have contributed to the multicentre case-control study ( Table 1 ). The methods used for the individual and multicentre case-control studies have been described elsewhere [21, 22, 25, [27] [28] [29] [30] 32] . In summary, each season the study site coordinators invite sentinel primary care practitioners belonging to the national sentinel surveillance systems to participate in the study. In Portugal, Italy, and Hungary, practitioners other than those participating in the sentinel surveillance system have been also invited to participate.
The study population in each case-control study consists of non-institutionalised patients consulting a participating practitioner for ILI or ARI (France) within eight days after symptom onset. The age groups and covariates included in the study have varied from one season to another (Table 2 ). Practitioners take nasal or throat swabs from all or a sample of ILI/ARI patients. From the We defined a case of influenza as an ILI patient who tests positive for influenza using reverse transcription polymerase chain reaction (RT-PCR) or culture. Controls are ILI patients testing negative for influenza (test-negative controls). Depending on the study site, testing is performed at national or regional reference laboratories. All laboratories testing sentinel specimens within the EISN scheme are part of a community network of reference laboratories (CNRL), which undergo periodic external quality assessments for virus detection and characterisation methods [34] .
The sentinel practitioners interview the ILI/ARI patients face-to-face, collect information on a set of predefined variables common to all study sites (Table 1) and send the completed questionnaires to each of the I-MOVE study site coordinators.
National study teams send to the EpiConcept coordination team anonymised databases of recruited ILI cases. We evaluate heterogeneity between studies qualitatively and quantitatively [35, 36] . We estimate the pooled IVE using a one-stage method, with the study site included as fixed effect in the model. a EU ILI definition: sudden onset of symptoms and at least one of the following four systemic symptoms: fever or feverishness, malaise, headache, myalgia and at least one of the following three respiratory symptoms: cough, sore throat, shortness of breath [33] . b ILI case definition used in Italy: sudden onset of fever, temperature >38 °C and cough or sore throat in the absence of another diagnosis c Italy: one person aged >64 years swabbed per week in 2010/11. d Hungary and Portugal: any hospitalisation in previous 12 months. e Obesity defined based on body mass index (≥30 in FR, IT, PO, PT; ≥35 in HU; ≥40 IE, ES); defined as "Obesity Yes/No/Unknown" in RO. All cases included in the 2009/10 study were laboratory confirmed as influenza A(H1N1)pdm09. Therefore, the effectiveness of the monovalent pandemic vaccine (72%; 95% CI: 48 to 85) was pandemic strain specific. Estimates of the trivalent 2010/11 seasonal vaccine effectiveness were lower than the pandemic IVE: 52% (95% CI: 30 to 67) overall, 51% (95% CI: 17 to 71) against influenza A(H1N1)pdm09 and 56% (95% CI: 34 to 71) when restricting the analysis to the target group for vaccination (Figure 2 ). In the age group 15-54 years, the point estimate for the pandemic vaccine effectiveness (73%) was higher than the point estimate for the effectiveness of the trivalent seasonal vaccines in 2009/10 (65%) and 2010/11 (47%). In the 2011/12 season, preliminary results (April 2012) suggested an overall low adjusted effectiveness (27 %) against influenza A(H3N2) among persons targeted for vaccination [24] . In Spain, early (25 December 2011 to 19 February 2012) IVE in the target population was 54% [19] .
Cohort studies
Four study sites have conducted cohort studies (Table  1) . These studies are based on electronic primary care databases that, using a unique identifier, can be linked
Figure 2
Adjusted overall and stratified influenza vaccine effectiveness against medically attended laboratory-confirmed influenza, The bars represent 95% confidence intervals.
I-MOVE: Influenza monitoring vaccine effectiveness.
a Adjusted for previous season influenza vaccination, at least one chronic disease, sex, at least one hospitalisation in previous 12 months, current smoker, age group (not included in the age-group strata), functional status. b Adjusted for any influenza vaccination in the two previous seasons, 2009/10 seasonal influenza vaccination, at least one chronic disease, sex, at least one hospitalisation for chronic disease in previous 12 months, current smoker, age group, practitioners vists in previous 12 months, month of symptom onset. c Adjusted for influenza vaccination in previous 2 seasons, at least one chronic disease, sex, at least one hospitalisation for chronic disease in previous 12 months, current smoker, age group, practitioners visits in previous 12 months, week of symptom onset. Table 3 Variables collected, data sources and timing of data extraction in I-MOVE cohort studies in Navarre (Spain), Royal College of General Practitioners (England and Wales) and Scotland, influenza season 2011/12
to other databases such as a vaccination registry, hospital admissions or laboratory databases. The linkage of the databases provides information on exposure, various outcomes and potential confounding factors or effect modifiers (Table 3) . Consequently, using a person-time analysis, cohort studies estimate adjusted IVE against various clinical outcomes (ILI, ARI, lower respiratory tract infection, hospital admission and death). In the 2010/11 season, the size of the cohorts varied from 93,380 individuals in Scotland to 1,005,132 in England.
Within the cohort studies, nested test-negative casecontrol studies are conducted to estimate IVE against medically attended laboratory-confirmed influenza [14, 16, 17, 20, 26] . During the 2009/10 season, the cohort in Scotland gave an estimated adjusted IVE of 49% (95% CI: 19 to 67) for ILI, of 40% (95% CI: 18 to 56) for overall mortality and of 60% (95% CI: −38 to 89) for virologically confirmed symptomatic individuals [20] . During the same season, the cohort study in England and Wales estimated an adjusted IVE of 21% (95% CI: 5.3 to 34.0) in preventing ILI and of 64% (95% CI: −6 to 88.6) in preventing PCR-confirmed influenza A(H1N1)pdm09 [18] . The Navarra cohort (Spain) results were similar: vaccination with the 2009 pandemic vaccine was associated with an adjusted 32% (95% CI: 8 to 50) reduction in the overall incidence of medically attended ILI and an adjusted 89% (95% CI: 36 to 100) reduction in the incidence of PCR-confirmed influenza [15] .
Screening method studies
In addition to estimating IVE using a cohort or a casecontrol study, some study sites use the screening method (Table 1 ). In the screening method, IVE is estimated by comparing the vaccination coverage between ILI patients positive for influenza and a reference group. The reference groups used in I-MOVE studies vary by study site and include the vaccination coverage in the practitioners´ catchment area (e.g. Spain, Scotland, England), the vaccination coverage in a random sample of the population (Portugal [25] ) or in the general population (Italy [31] ). The Farrington method [38] is used to adjust IVE for age group (Spain, Italy, Portugal, Scotland), risk group (Portugal, Scotland), GP practice (Scotland) and socio-economic status (Scotland). During the pandemic and in line with results using other study designs, the I-MOVE screening method studies estimated a high pandemic IVE against medically attended laboratory-confirmed influenza A(H1N1)pdm09: the IVE was 78% (95% CI: 61 to 88) in the Spanish study [39] and 92% (95% CI: 46 to 99) in the Italian [31] .
Conclusion
The I-MOVE network is well established and has provided seasonal and pandemic IVE for four consecutive influenza seasons (2011/12 results have been submitted for publication). The I-MOVE results are timely: since the 2009/10 season, preliminary results have been communicated early in the season to the decision-makers and published in peer-reviewed journals [15, 19, 23, 24, 29] .
I-MOVE results have assisted in guiding public vaccination policy at national and European level. In particular, during the 2009 pandemic they contributed to the riskbenefit analysis process coordinated in the EU by the EMA [40] and globally by WHO [41] by providing regular updates of IVE estimates. In 2012, the low observed IVE against influenza A(H3N2) prompted a discussion on the respective role of antigenic drift and early waning immunity [19, 24] . In addition, the European regulatory authority (EMA) incorporated I-MOVE estimates as a component of post-licensure surveillance for the 2009 pandemic vaccines [42] . As the I-MOVE IVE studies are conducted by an independent scientific research network, this adds weight to the integrity of their results and to how they are perceived professionally and by the public.
Using a sound methodology, I-MOVE studies have shown that seasonal IVE is moderate against medically attended laboratory-confirmed influenza. This is triggering a number of initiatives including a possible revision of EU regulatory criteria for annual vaccine relicensure that include results of IVE studies [43] . Given the timely provision of in-season estimates of IVE from I-MOVE and similar networks elsewhere in the world, discussions are ongoing with WHO to consider how such estimates can contribute to the annual vaccine strain selection process [44] .
During the 2009/10 pandemic season, all the I-MOVE network participants (practitioners, laboratories, national and regional public health institutes) were overwhelmed with response activities. Having the I-MOVE coordinating hub based in a structure not directly involved in the response was an advantage: the studies were not disrupted and the coordination hub could focus on facilitating exchanges between study sites, on rapidly analysing the multicentre casecontrol study and on coordinating the communication of IVE results to ECDC.
I-MOVE is a unique platform for exchanging views on and experience of methods to estimate IVE. During the I-MOVE technical workshops and annual meetings, the discussions around the epidemiological and logistic challenges allowed improvement of standard methods, good scientific practices to be followed and have strengthened EU expertise on IVE. The network has contributed to strengthening influenza surveillance in the EU. Currently, most of the sentinel practitioners conducting I-MOVE studies use the same EU ILI case definition and select patients for swabbing in a systematic way. As most I-MOVE practitioners are part of the national sentinel surveillance systems, any improvement and standardisation of methods should have a positive impact on national and European influenza surveillance systems.
The I-MOVE network takes into account the operational and methodological aspects required to building a sustainable system: studies are methodologically sound but at the same time feasible within existing surveillance systems and with limited resources. The estimates include effectiveness against medically attended laboratory-confirmed influenza as outcome and are adjusted for the main confounding factors described in the literature (e.g. presence of underlying chronic diseases, health-seeking behaviour, age group, etc.). In addition, the availability of various study designs, settings and outcomes gives a combination of different sets of evidence, facilitating better interpretation of the results.
The challenges for monitoring IVE in Europe include the variety of influenza vaccines available and in use and differences in vaccination coverage and groups targeted for vaccination and in health-seeking behaviours between Member States [45] . Having estimates by vaccine type and among target groups represents a major challenge and requires large sample sizes. The constant increase in sample size observed throughout the four influenza seasons and the precise information collected on vaccine type and brand could allow estimation of IVE by vaccine type in the near future. Time, especially during a pandemic, needs to be accounted for in the analysis (e.g. adjustment for week/month of symptom onset, person-time analysis in the cohort studies). The main limitation in reaching a large sample size is the low influenza vaccination coverage in some groups [46] . Pooling data from the various I-MOVE case-control studies is one of the I-MOVE strengths that allows IVE to be estimated early in the season and for different subgroups. In 2010/11, we had for the first time IVE estimates for the target groups for vaccination [22] . However, results still lack sufficient precision and efforts should be made to increase the sample size in each study site.
In I-MOVE, the cohort study in the Navarre region of Spain is the only study able to provide early and repeated estimates of IVE against hospital admission of persons with laboratory-confirmed influenza [16] . Therefore, one of the limitations of I-MOVE is that it does not yet provide early estimates of IVE against severe outcomes at European level. The main challenge is to attain a sufficient sample size enabling precise adjusted estimates and stratification by effect modifiers. A European hospital network with multiple sites using the same protocol would allow a multicentre study to be conducted with a sample size sufficient to rapidly estimate IVE against severe influenza outcomes. As a first step, the I-MOVE network has developed a generic protocol for IVE hospital casecontrol studies. From the 2011/12 season, hospitals in the Valencia and Navarre regions (Spain), France and Italy are conducting studies based on this protocol and are providing pooled estimates of IVE against hospital admissions with laboratory-confirmed influenza.
Some countries considered that the screening method, in addition to case-control and cohort studies, was convenient because of its inexpensiveness, reliance on already available data and ability to provide an early indication of IVE.
Influenza sentinel surveillance networks have shown to be an excellent framework in which IVE observational studies can be conducted using different study designs (cohort, case-control and screening method) not only in Europe but also in other countries such as Canada or Australia [47, 48] . The scientific knowledge and experience in practical, managerial and logistic issues gained by the I-MOVE network can be used in other regions of the world to estimate IVE. The I-MOVE model can also be adapted to establish similar monitoring systems in Europe for vaccines that may change their effectiveness over time due to, for example, serotype replacement or to changes in vaccination schedules (e.g. rotavirus, pneumococcal conjugate vaccine). I-MOVE experience, protocols and some of the study sites infrastructures are already contributing to a recent ECDC project for assessing vaccination impact and effectiveness studies for pneumococcal conjugate vaccine [49] .
There is a strong case for use of the I-MOVE methodology for monitoring IVE as a routine part of postlicensure monitoring. The approach described in this article is ethical and practical. While it cannot have the accuracy of randomised controlled trials, the results achieve their objective in detecting changes in effectiveness over time and with changes in vaccine.
The major challenge is how to make these studies sustainable. While they are not as expensive as randomised controlled trials, they are not as inexpensive as the sentinel surveillance undertaken by the same practitioners. Nevertheless, they require accurate virus testing and careful coordination to retain quality.
What has yet to be resolved is how to attract co-sponsorship from industry and public sectors while retaining independence. Some manufacturers appreciate the advantages to them of having such validation as do regulators. However, a way of combining monies in a share scheme has yet to be achieved. The recent breakthrough of agreement for sustaining WHO's essential influenza surveillance work may show the way forward [50] . (participation during influenza seasons 2008/9 to 2011/12) 
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